tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inventiva Announces Preliminary First-Half 2025 Financial Results

Story Highlights
  • Inventiva reported €122.1 million in cash and €24.6 million in deposits as of June 2025.
  • Inventiva’s first-half 2025 revenues reached €4.5 million, driven by milestone payments.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Inventiva Announces Preliminary First-Half 2025 Financial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Inventiva ( (IVA) ).

On July 29, 2025, Inventiva reported its preliminary financial results for the first half of 2025, revealing cash and cash equivalents of €122.1 million and short-term deposits of €24.6 million as of June 30, 2025. The company recorded revenues of €4.5 million, primarily from milestone payments related to its structured financing and licensing agreement with Chia Tai Tianqing Pharmaceutical Group. Inventiva’s net cash used in operating activities increased due to working capital changes and a pipeline prioritization plan. The company anticipates that its current financial resources will support operations until the end of the third quarter of 2026, though additional funds will be needed for long-term objectives.

The most recent analyst rating on (IVA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.

Spark’s Take on IVA Stock

According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.

Inventiva’s overall stock score reflects severe financial difficulties and valuation concerns, tempered by some technical indicators and cautious optimism from strategic developments. The ongoing financial instability is the most significant factor affecting the score.

To see Spark’s full report on IVA stock, click here.

More about Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for treating metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for treating adult patients with MASH. Inventiva is publicly listed on Euronext Paris and the Nasdaq Global Market.

Average Trading Volume: 20,335

Technical Sentiment Signal: Sell

Current Market Cap: $442.9M

See more data about IVA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1